読み込み中
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.
前日終値
$2.00
−$0.045 · -2.20%
日中の時刻はETです。市場データは遅延する場合があります。
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.
日中レンジ
現在 $2.00
52週レンジ
現在 $2.00
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
66
割安
センチメント
49
まちまち
リスク
66
高リスク
モメンタム
17
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.
日中レンジ
現在 $2.00
52週レンジ
現在 $2.00
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 229.33万 USD | 162.91万 USD | 107.2万 USD | 120.62万 USD | 117.97万 USD |
| 売上原価 | 87.24万 USD | 54.49万 USD | 38.01万 USD | 44.19万 USD | 37.04万 USD |
| 粗利益 | 142.09万 USD | 108.42万 USD | 69.19万 USD | 76.43万 USD | 80.93万 USD |
| 研究開発 | 757.77万 USD | 821.65万 USD | 720.87万 USD | 581.38万 USD | 408.43万 USD |
| 販売・一般管理 | 1108.98万 USD | 1035.61万 USD | 750.81万 USD | 598.96万 USD | 447.07万 USD |
| 営業費用 | 1900.96万 USD | 1887万 USD | 1520.03万 USD | 1236.45万 USD | 914.61万 USD |
| 受取利息 | 10.18万 USD | 58.24万 USD | 43.1万 USD | 22.82万 USD | 3768 USD |
| 支払利息 | 189.11万 USD | 160.36万 USD | 16.54万 USD | 1.35万 USD | 1.92万 USD |
| 減価償却費と償却費 | 85.04万 USD | 87.2万 USD | 90.8万 USD | 88.91万 USD | 96.43万 USD |
| 営業利益 | −1758.87万 USD | −1778.58万 USD | −1450.84万 USD | −1160.03万 USD | −833.68万 USD |
| 純利益 | −1862.79万 USD | −1881.66万 USD | −1424.71万 USD | −1139.42万 USD | −753.78万 USD |
会社概要が更新されました 2026年10月11日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
